Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071589 | 0.89 | MAPK14 (0.46) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL3993149 | 0.87 | MAPK14 (0.43) | MAPK14 | |
| SCHEMBL4061444 | 0.84 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL4065944 | 0.76 | MAPK14 (0.43) | MAPK14 | |
| SCHEMBL3989220 | 0.75 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL3990762 | 0.75 | MAPK14 (0.57) | MAPK14CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL3990758 | 0.72 | MAP2K3 (0.54) | MAPK14CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL4558663 | 0.70 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL4530046 | 0.67 | PTGES (0.40) | MAPK14 | |
| SCHEMBL3997933 | 0.67 | MAPK14 (0.51) | MAPK14CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1713805-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075478-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPK14 174/4885CSNK1D 120/4885CSNK1E 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.